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Vasculopathy With Single or Multiple PolypsMISA SUZUKI, NORIHIRO NAGAI, HAJIME SHINODA, ATSURO UCHIDA, TOSHIHIDE KURIHARA,
YOHEI TOMITA, MAMORU KAMOSHITA, CHIGUSA IYAMA, KAZUO TSUBOTA, AND YOKO OZAWA PURPOSE: To understand the prognosis of polypoidal
choroidal vasculopathy (PCV) by evaluating the respon-
siveness to intravitreal ranibizumab (IVR) monotherapy
according to the presence of a single or multiple polyps.
 DESIGN: Retrospective case series.
 METHODS: We included 48 treatment-naı¨ve eyes of 48
patients who received IVR monotherapy at the Medical
Retina Division Clinic, Keio University Hospital be-
tween March 2009 and January 2013 and attended the
clinic for at least 12 months. All patients received
3 monthly IVR injections followed by pro re nata injec-
tions and were divided into single polyp and multiple
polyps groups according to indocyanine green angiog-
raphy and optical coherence tomography (OCT) findings.
The outcome measures included changes in best-
corrected visual acuity (BCVA) and OCT findings over
2 years after initial IVR.
 RESULTS: At baseline, the multiple polyps group
exhibited a poorerBCVA, larger greatest linear dimension,
and higher prevalence of fibrovascular pigment epithelial
detachment compared with the single polyp group. Over
2 years, themultiple polyps group showed no improvement
in BCVA, although the central retinal thickness (CRT)
decreased in both groups. The multiple polyps group
exhibited a significantly greaterCRTat1year and required
more injections in the first year compared with the single
polyp group; furthermore, it included a higher number of
nonresponders judged either by BCVA or fundus findings
at 1 year and fundus findings at 2 years.
 CONCLUSIONS: We propose that the stratification of
PCV lesions according to the presence of single or multiple
polypsmaybevaluable tounderstand the prognosis. (Am
J Ophthalmol 2016;166:52–59.  2016 The Authors.
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 2016 THE AUTHORS. PUBR
ECENT PROGRESS INMOLECULAR TARGETING THER-
apies has improved the overall prognosis of age-
related macular degeneration (AMD), a leading
cause of blindness worldwide. While most patients receive
benefits from treatment with intravitreal anti–vascular
endothelial growth factors (anti-VEGFs) such as ranibizu-
mab (IVR)1,2 and aflibercept (IVA),3 treatment response
is not always consistent among patients.4–8 This can be
attributed to differences in the pathogenesis of AMD
among individuals.
Generally, AMD is divided into 3 subtypes: typical
AMD, polypoidal choroidal vasculopathy (PCV), and
retinal angiomatous proliferation (RAP).9 PCV, which
accounts for almost 50% of AMD patients in Asian coun-
tries,10,11 is characterized by polypoidal lesions with or
without a branching vascular network (BVN) detected by
indocyanine green angiography (ICGA).12 Most patients
with PCV exhibit unilateral disease, similar to those with
typical AMD, and do not frequently develop drusen in
the unaffected eye, as opposed to RAP, which carries a
poorer prognosis compared with PCV and typical
AMD.13 Because of differences in the clinical course and
therapeutic response,14 it is important to differentiate be-
tween PCV and typical AMD, although patients with
both PCV and typical AMD in a single eye have also
been reported.15 Moreover, reports of the posttreatment
prognosis of PCV patients are inconsistent among clinical
studies.16–21 For example, a randomized study (the
EVEREST study) compared the efficacy of IVR and
photodynamic therapy (PDT) for the treatment of PCV
and concluded that the latter was more effective in
achieving polyp regression.16 In contrast, another study
(the LAPTOP study) showed that IVR monotherapy was
superior to PDT.17 These differences probably occurred
because of the lack of detailed classifications for the
different variants of PCV that exhibit different responses
to treatment. Therefore, classifications that accurately
represent the prognosis of each variant are desirable.
We previously reported that nonresponders to IVR
among patients with different subtypes of AMD exhibit
unique fundus findings at baseline.4 In the same study,
initial fibrovascular pigment epithelial detachment
(PED), serous PED, and type 1 choroidal neovasculariza-
tion were found to be associated with a lack of response
to IVR. In the current study, we divided PCV patients0002-9394
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into 2 groups on the basis of the presence of a single or mul-
tiple polyps and retrospectively analyzed their responsive-
ness to IVR monotherapy to derive information that will
aid in understanding the pathologic course and predicting
the prognoses of patients with different variants of PCV
treated by IVR monotherapy.METHODS
THIS RETROSPECTIVE CASE SERIES WAS BASED ON A
detailed medical chart review, followed the tenets of the
Declaration of Helsinki, and was retrospectively approved
by the Ethics Committee of Keio University School of
Medicine (No. 2010002) and registered with UMIN-
CTR (UMIN000007649).
 STUDY PARTICIPANTS: In total, 68 consecutive eyes of
65 patients were diagnosed with PCV. From these, we
included 48 eyes of 48 patients with PCV-induced visual
loss who received IVR monotherapy at the Medical Retina
Division Clinic (AMD Clinic) of the Department of
Ophthalmology, Keio University Hospital (Tokyo, Japan)
betweenMarch 2009 and January 2013. During this period,
aflibercept, which was first approved in Japan in November
2012, and another off-label anti-VEGF drug for AMD,
bevacizumab, were not used at the hospital. Thus, all
PCV patients who needed anti-VEGF therapy were treated
with IVR. All patients had attended our clinic for at least
12 months, during which time no medication other than
IVRwas administered. Patients who had received any other
treatment for AMD in the past were excluded; thus, all par-
ticipants were treatment naı¨ve. All patients who began
receiving treatments other than IVR monotherapy after
the first year were considered dropouts, and their data
before the initiation of another treatment were analyzed.
All patients provided informed consent for the use of their
data for research purposes.
 OPHTHALMOLOGIC EXAMINATIONS: All patients
underwent best-corrected visual acuity (BCVA) measure-
ments using refraction tests, slit-lamp examinations, and
binocular indirect ophthalmoscopy after pupil dilation
with 0.5% tropicamide throughout the study.
 FLUORESCEIN AND INDOCYANINE GREEN ANGIOGRA-
PHIES: Fluorescein angiography and ICGAwere performed
for AMD diagnosis and PCV definition using a Topcon
TRC 50DX retinal camera (Topcon Corporation, Tokyo,
Japan). According to the findings of ICGA and optical
coherence tomography (OCT), the patients were divided
into the single polyp and multiple polyps groups (Figure 1).
 OPTICAL COHERENCE TOMOGRAPHY: OCT was
performed at every follow-up visit using a Heidelberg Spec-VOL. 166 POLYPOIDAL CHOROIDAL VASCULOtralis OCT system (Heidelberg Engineering GmbH,
Dossenheim, Germany). The OCT images were used to
evaluate central retinal thickness (CRT), central choroidal
thickness (CCT), and AMD lesions, including PED. CRT
was defined as the distance between the internal limiting
membrane and the presumed retinal pigment epithelium
(RPE) at the fovea. CCT was defined as the distance
from the hyperreflective line corresponding to the Bruch
membrane beneath the RPE and the inner surface of the
sclera at the foveal center, and was manually measured us-
ing the caliper function of the OCT device. Measurements
were obtained using the scale bars of the OCT system for
reference. A dry macula was defined as the resolution of
intra- and subretinal fluid detected by OCT with reference
to fundus findings, and in particular to an increase or
decrease in hemorrhages. Changes in hemorrhages (eg,
retinal or subretinal hemorrhage or hemorrhagic PED)
were not always detected by OCT, but could respond to
AMD activity. Thus, we also checked fundus photography
and excluded those who had increased hemorrhagic find-
ings from the patients with dry macula.
 INTRAVITREAL RANIBIZUMAB MONOTHERAPY AND
FOLLOW-UP: In the induction phase, ranibizumab
(0.5 mg, 0.05 mL) was intravitreally injected via the pars
plana under sterile conditions once a month for 3 months.
The injections were repeated if follow-up OCT showed
evidence of any fluid in the macula, identified as macular
edema, subretinal fluid, or PED enlargement. Follow-ups
were generally conducted every month after therapy initi-
ation, but in cases where no fluid or hemorrhage was
detected for more than 2months, the interval was extended
up to 2 months. Any new intra- or subretinal hemorrhage
or unexplained visual loss represented by an increase of
>0.2 in logMAR BCVA was treated as appropriate. At
each follow-up visit, BCVA was measured and other
ophthalmologic examinations, including OCT, were
performed.
 DEFINITION OF NONRESPONDERS TO INTRAVITREAL
RANIBIZUMAB: Nonresponders were defined on the basis
of BCVA or fundus findings, as previously reported.4
Briefly, patients with an increase of >0.2 in logMAR score
at 1 or 2 years after initial IVR therapy were judged as non-
responders on the basis of BCVA. On the basis of fundus
findings, nonresponders were judged as patients with aggra-
vated or fresh exudative fundus findings (PED, subretinal
fluid, macular edema, or hemorrhage) even after treatment,
or those with an increase of >100 mm in CRT between
baseline and 1 or 2 years after initial IVR therapy.
 STATISTICAL ANALYSES: Data are expressed as means
6 standard deviations (SDs). Commercially available soft-
ware (SPSS, version 21.0; SPSS Japan, Tokyo, Japan) was
used for all statistical analyses. The Mann-WhitneyU test,
x2 test, multiple regression analyses, or Spearman rank53PATHY WITH MULTIPLE POLYPS
TABLE 1. Baseline Characteristics of the Single Polyp and
Multiple Polyps Groups
Single Polyp Multiple Polyps P Value
Age (y) 72.1 6 9.4 72.7 6 7.5 .72
Sex, male [female] 22 [7] 12 [7] .517
Best-corrected visual
acuity (logMAR)
0.18 6 0.26 0.37 6 0.30 .017a
Greatest linear
dimension (mm)
2950.8 6 3237.3 4084.4 6 1926.4 .009b
Central retinal
thickness (mm)
394.6 6 156.8 384.1 6 183.6 .591
Central choroidal
thickness (mm)
218.9 6 61.7 251.3 6 85.7 .117
Fibrovascular retinal
pigment epithelial
detachment, eyes
[%]
5 [29%] 11 [57.9%] .004b
Follow-up period
(mo)
22.5 6 3.2 20.7 6 4.8 .116
For sex, the x2 test was used to evaluate comparisons, and the
Mann-Whitney U test was applied for the other comparisons.
aP < .05.
bP < .01.
FIGURE 2. Mean best-corrected visual acuity (BCVA) after
intravitreal ranibizumab (IVR) monotherapy in polypoidal
choroidal vasculopathy patients in the single polyp and multiple
polyps groups. The mean BCVA shows a significant improve-
ment at all time points of assessment after initial IVR therapy
in the single polyp group, while that in the multiple polyps group
shows no change. Significant differences are observed between
the groups at baseline and at all time points of assessment after
initial IVR therapy. *P < .05, **P < .01 by the Mann-
Whitney U test.
FIGURE 1. Representative angiograms of polypoidal choroidal vasculopathy patients in the single polyp andmultiple polyps groups at
baseline. Indocyanine green angiography shows a single polyp (Left, top 2 images) and multiple polyps (Right, top 2 images) in both
the early and late phases. Optical coherence tomography shows exudative changes at baseline (Left, bottom: single polyp group; Right,
bottom: multiple polyps group).correlation coefficient was used for comparisons, and a
P value of <.05 was considered statistically significant.
RESULTS
AMONG THE 48 PCV TREATMENT-NAI¨VE PATIENTS, 29 EYES
of 29 patients (22 men and 7 women) exhibited a single
polyp and 19 eyes of 19 patients (12 men and 7 women)54 AMERICAN JOURNAL OFexhibited multiple polyps on baseline ICGA before IVR
treatment. Among the multiple polyps group, 2, 3, 4, 5,
6, 7, and 12 polyps were found in 4, 4, 3, 1, 3, 3, and 1 pa-
tient, respectively. There were 5 dropouts in the second
year of treatment, including 1 patient in the single polyp
group who was lost to follow-up, 1 patient each in both
groups who changed their treatments, and 2 patients in
the multiple polyps group who underwent vitrectomy for
PCV-associated vitreous hemorrhage.
At baseline, the mean BCVA was significantly poorer in
the multiple polyps group than in the single polyp group
(Table 1, P¼ .017), while the mean greatest linear dimen-
sion (GLD) was larger in the multiple polyps group than inJUNE 2016OPHTHALMOLOGY
FIGURE 3. Changes in best-corrected visual acuity (BCVA) at 1 and 2 years after initial intravitreal ranibizumab (IVR) therapy in
polypoidal choroidal vasculopathy patients in the single polyp and multiple polyps groups. The number of patients with improved or
maintained BCVA at 1 year after initial IVR therapy was significantly smaller in the multiple polyps group than in the single polyp
group (P[ .019, Mann-Whitney U test).
FIGURE 4. Mean central retinal thickness (CRT) after intravi-
treal ranibizumab (IVR) therapy in polypoidal choroidal vascul-
opathy patients in the single polyp and multiple polyps groups.
In both groups, the mean CRT was decreased at all time points
after initial IVR therapy relative to that at baseline. A signifi-
cant difference is observed between the 2 groups at 1 year.
**P< .01 by the Mann-Whitney U test.the single polyp group (P ¼ .009). Furthermore, the num-
ber of eyes with fibrovascular PED (f-PED), as detected
by fluorescein angiography and OCT, was greater in the
multiple polyps group than in the single polyp group
(P¼ .004). All f-PED lesions corresponded to the presence
of a BVN in the multiple polyps group. There was no signif-
icant difference in age, sex, baseline CRT, baseline CCT,
or follow-up duration between the 2 groups.
ThemeanBCVA in the single polyp group showed signif-
icant improvement at each point compared with that at
baseline (Figure 2), while it remained unchanged in the
multiple polyps group. Moreover, the mean BCVA was
significantly poorer in the multiple polyps group than in
the single polyp group at all time points of assessment
(Figure 3; 3 months, P ¼ .04; 1 year, P ¼ .003; 2 years,
P ¼ .002), although there was no intergroup difference in
mean changes inBCVAat any time point (data not shown).
In total, 21 of 29 eyes (96.6%) in the single polyp group
and 14 of 19 eyes (72.2%) in the multiple polyps groups
showed maintained or improved BCVA at 1 year after
initial IVR therapy (P ¼ .019), while 21 of 27 eyes
(96.4%) and 13 of 16 eyes (81.3%), respectively, showed
maintained or improved BCVA at 2 years (P ¼ .262)
(Figure 3).
The mean CRT at 3 months exhibited a decrease rela-
tive to that at baseline and remained low throughout 2
years of treatment in both groups (Figure 4). At 1 year,
however, the mean CRT was significantly greater in the
multiple polyps group (297.56 127.4 mm) than in the sin-
gle polyp group (226.6 6 114.4 mm; P ¼ .009), with a
significantly smaller mean CRT change in the former
(101.2 6 116.1 mm) than in the latter (168.0 6
178.6 mm; P ¼ .042).
Interestingly, the numbers of IVR injections in the first
and second years were 4.4 6 2.1 and 1.7 6 2.0, respec-VOL. 166 POLYPOIDAL CHOROIDAL VASCULOtively, in the single polyp group and 6.0 6 2.5 and 2.3 6
2.4, respectively, in the multiple polyps group, indicating
a significant difference in the first year (Figure 5, P¼ .009).
Intra- and subretinal exudative changes had disappeared
after the initial 3 injections in 28 eyes (96.6%) in the single
polyp group and 15 eyes (78.9%) in the multiple polyps
group (Table 2); the eyes in the latter group showed a
greater tendency for residual exudative changes after the
induction phase (P ¼ .051). The mean number of injec-
tions required before the first complete disappearance of
intra- and subretinal exudative changes and the achieve-
ment of a dry macula were 3.4 6 1.4 and 4.9 6 3.3 in
the single polyp and multiple polyps groups, respectively
(Table 2; P ¼ .054). Among eyes in which a dry macula
was achieved, the durations between the last injection
before observation of a dry macula and the subsequent55PATHY WITH MULTIPLE POLYPS
FIGURE 5. Mean number of intravitreal ranibizumab (IVR)
injections in the first and second years in polypoidal choroidal
vasculopathy patients in the single polyp and multiple polyps
groups. The number of injections was significantly greater in
the multiple polyps group than in the single polyp group in the
first year, with no significant difference between the groups in
the second year. **P< .01 by the Mann-Whitney U test.
TABLE 2. Achievement of a Dry Macula in the Single Polyp
and Multiple Polyps Groups After Intravitreal Ranibizumab
Therapy
Single Polyp Multiple Polyps P Value
Dry macula after 3 initial
injections, eyes [%]
28 [96.6%] 15 [78.9%] .051
Number of injections to
obtain a dry macula
3.4 6 1.4 4.9 6 3.3 .054
Duration to retreatment (mo) 11.4 6 7.1 5.9 6 6.4 .003b
No injections for more than
1 year, eyes [%]
13 [44.8%] 2 [10.5%] .012a
The Mann-Whitney U test was applied to evaluate compari-
sons between the groups.
aP < .05.
bP < .01.injection for recurrence were 11.46 7.1 months and 5.96
6.4 months in the single polyp and multiple polyps groups,
respectively, with a significant difference between the
groups (Table 2; P ¼ .005). Fifteen eyes, including 13
(44.8%) in the single polyp group and 2 (10.5%) in the
multiple polyps group (Table 2; P ¼ .003), needed no
further injections for more than a year after the first remis-
sion.
The numbers of nonresponders as judged by BCVA were
1 (3.4%) and 6 (31.6%) in the single polyp and multiple
polyps groups, respectively, at 1 year (Figure 6); the corre-
sponding numbers were 0 (0%) and 5 (28.3%), respec-
tively, when fundus findings were used for judgment
(Figure 6). Thus, the number of nonresponders at 1 year
was significantly higher in the multiple polyps group than
in the single polyp group according to both criteria
(BCVA, P¼ .007; fundus findings, P¼ .004). A significant
difference was also observed on the basis of fundus findings
at 2 years (Figure 6; P ¼ .027).DISCUSSION
IN THIS STUDY, WE COMPARED THE RESPONSES OF PCV PA-
tients with a single polyp or multiple polyps to IVR mono-
therapy. The multiple polyps group exhibited a poorer
BCVA, larger GLD, and higher prevalence of f-PED at
baseline compared with the single polyp group. Although
the mean BCVA improved with treatment in the single
polyp group, it remained poor in the multiple polyps group
throughout the 2-year course, with significant differences
between the groups. Furthermore, CRT at 1 year after
initial IVR therapy was greater in the multiple polyps group
than in the single polyp group, although there was an
improvement relative to the thickness at baseline in both
groups. The multiple polyps group required more injections
in the first year, with a shorter period of remission after the56 AMERICAN JOURNAL OFinitial disappearance of exudative changes. Finally, the
number of nonresponders as judged by BCVA and/or
fundus findings was higher in the multiple polyps group at
1 and 2 years.
The multiple polyps group exhibited a poor baseline
BCVA with a high prevalence of f-PED, which generally
manifests after a long clinical course.22 This suggests that
the patients in the multiple polyps group had a longer path-
ologic history before the initial visit for treatment,
although further studies are required to clarify this specula-
tion. With regard to the increased GLD in this group, the
widespread polyps around the BVNmay have played a role.
The mean CRT decreased after 3 months of initial treat-
ment in both groups, indicating a benefit from anti-VEGF
therapy. However, the mean CRT change at 1 year was
significantly smaller in the multiple polyps group than in
the single polyp group, indicating a difference in treatment
responsiveness. Given that pro re nata retreatment was
administered, this is consistent with the finding of a higher
mean injection rate in the multiple polyps group in the first
year. Furthermore, compared with the single polyp group,
the multiple polyps group exhibited a higher prevalence
of residual fluid after 3 IVR injections and a shorter mean
interval before the recurrence of exudative changes after
the first remission. These findings suggest that intra- and
subretinal exudative changes were rather resistant to IVR
and easily recurred in the presence of multiple polyps.
Consistent with these findings, the number of eyes with a
decreased BCVA was higher in the multiple polyps group
at 1 year after initial IVR therapy, most probably because
these eyes were exposed to exudative changes during every
recurrence, which resulted in an overall longer duration of
exposure.
Tsujikawa and associates reported that widespread PCV
with a GLD of more than 1 disc area (DA) was associated
with a poorer prognosis compared with PCV involving a
smaller area.5 Although the criteria for stratification wereJUNE 2016OPHTHALMOLOGY
FIGURE 6. Number of nonresponders to intravitreal ranibizumab (IVR) therapy at 1 and 2 years among polypoidal choroidal vascul-
opathy patients in the single polyp and multiple polyps groups. The number of nonresponders to IVR therapy at 1 year after initial
IVR therapy was significantly greater in the multiple polyps group than in the single polyp group according to both best-corrected
visual acuity and fundus findings. A similar difference was also observed on the basis of fundus findings at 2 years. **P< 0.01
by the x2 test.different in our study, the multiple polyps group exhibited a
larger GLD at baseline and a worse prognosis with regard to
both CRT and BCVA after IVR monotherapy. The previ-
ous study showed that widespread PCV was characterized
by an increase in GLD after anti-VEGF treatment and
was associated with single nucleotide polymorphisms
(SNPs), type 2 choroidal neovascularization (CNV), PED
covering an area larger than 1 DA, and an increased inci-
dence of massive hemorrhage. Similarly, the multiple
polyps group in the present study exhibited a higher prev-
alence of f-PED, although it remains unclear whether the
PED observed in the previous study5 was of the fibrous
type. On the other hand, the multiple polyps group and sin-
gle polyp group in the present study included 10 (52.6%)
and 11 eyes (37.9%) with type 2 CNV and 1 (5.3%) and
3 eyes (10.3%) with massive hemorrhages covering areas
larger than 5 DA, respectively, with no significant differ-
ence between the groups (data not shown).
Kawamura and associates categorized PCVs according to
the presence or absence of feeder and draining vessels to
analyze the characteristics in a cross-sectional manner,23VOL. 166 POLYPOIDAL CHOROIDAL VASCULOwhile Yanagisawa and associates reported that PCV
without feeder or draining vessels was associated with an
elastin SNP.24 However, these reports did not mention
the prognosis of each group. In addition to our study, these
studies and others23,25–28 support the fact that PCV may
have further distinct classifications with different
phenotypes.
We previously analyzed nonresponders to IVR among pa-
tients with all AMD subtypes, typical AMD, PCV with a
single ormultiple polyps, andRAP and found nonresponder
percentages of 14.9% and 17.0% as judged by BCVA and
fundus findings at 1 year, respectively.4 Compared with
the proportion of nonresponders among patients with all
AMD subtypes in the previous study, the present study
demonstrated a larger proportion in the multiple polyps
group and a lower proportion in the single polyp group.
Furthermore, our previous study reported that f-PED was a
risk factor among patients with all AMD subtypes for lack
of response to IVR according to BCVA and fundus findings,
and this was consistent with the higher prevalence of f-PED
in the multiple polyps group in the present study.57PATHY WITH MULTIPLE POLYPS
However, the presence or absence of f-PED did not affect
nonresponsiveness as judged by BCVA at 1 year by multi-
ple regression analysis after adjusting for age, sex, and the
presence of multiple polyps. However, the presence of mul-
tiple polyps did have an effect after adjusting for age, sex,
and the presence of f-PED (Supplemental Table 1, avail-
able at AJO.com). Moreover, GLD, which was larger in
the multiple polyps group, did not affect nonresponsiveness
as judged by BCVA at 1 year or the number of injections in
the first year, as the multiple regression analyses showed af-
ter adjusting for age, sex, and polyp multiplicity. However,
multiple polyps did have an effect by a similar method with
adjustments for age, sex, and GLD (Supplemental Tables 2
and 3, respectively; available at AJO.com). No additive ef-
fect was observed to differentiate nonresponders to IVR
into details according to levels of risk, even when the other
PCV components, such as f-PED and GLD, were combined
with polyp multiplicity for analyses (data not shown).
Moreover, there was no difference in the duration of a
dry macula when eyes were stratified according to the pres-
ence or absence of f-PED; nevertheless, among the 11 eyes
with f-PED in the multiple polyps group, only 1 (9.1%)
remained in remission for more than 1 year, while 4 of 5
eyes (80%) in the single polyp group remained free of
exudative changes for over 1 year (data not shown). In
contrast, there was a difference when eyes were stratified
by polyp multiplicity. These results suggest that polyp mul-
tiplicity, but not other PCV components such as f-PED, was
responsible for the prognosis.
Interestingly, the number of polyps at baseline was corre-
lated with BCVA at 1 and 2 years, as well as at baseline,
respectively (Supplemental Table 4, available at AJO.
com), although the number of polyps itself was not corre-
lated with responsiveness to IVR, as long as the patients
had multiple polyps. Neither GLD nor f-PED at baseline
was correlated with BCVA at 1 or 2 years (data not shown).
These facts also support the impact of polyp multiplicity in
visual prognosis.58 AMERICAN JOURNAL OFThus, although the pathologic relationship between
f-PED and exudative changes requires further study, the
current observations support the importance of classifica-
tions by the presence or absence of multiple polyps for
predicting the prognosis of PCV.
Mori and associates also reported that only 19% of PCV
eyes showed a regression of polyps after 1 year of anti-VEGF
therapy,29 while the EVEREST study reported that the
regression rate for polyps after 6 months of treatment was
28.6% in the IVR monotherapy group and 77.8% in the
verteporfin PDT with IVR group.16 These findings suggest
that IVR monotherapy is not very effective for the regres-
sion of polyps. This may also partly explain the increased
recurrence after IVR monotherapy in the multiple polyps
group in the current study, where there was a greater likeli-
hood of remaining nonregressed polyps because of the
initially large number of polyps and formation of new
polyps.
The difference in responsiveness to IVR between the
single and multiple polyps groups could be one reason for
the discrepancy in clinical outcome between the EVER-
EST study16 and the LAPTOP study.17 Thus, it would be
interesting to evaluate the effects of adjunctive therapies
in PCVs with multiple polyps in a future study.
This study had some limitations. First, we did not record
angiograms for most eyes during the treatment course. Sec-
ond, we did not assess the relationship between residual
lesions, including polyps and/or BVN, and the prognosis.
Third, we did not investigate SNPs, and fourth, the sample
size in this study was small. In addition, this was a retrospec-
tive study, and not all patients were examined monthly
during the study.
In conclusion, the results of our study suggest that the
response to IVR therapy is poorer in PCV patients with
multiple polyps than in those with a single polyp. Although
further studies are required, we propose that the stratifica-
tion of PCV lesions by polyp number may be valuable to
understand the prognosis of this condition.FUNDING/SUPPORT: NO FUNDINGOR GRANT SUPPORT. FINANCIAL DISCLOSURES: MISA SUZUKI: PFIZER JAPAN INC, NOVARTIS
Pharmaceuticals Japan. Norihiro Nagai: Santen Pharmaceutical Co Ltd, Bayer AG. Hajime Shinoda: Alcon Research LTD. Atsuro Uchida: award from
Alcon Research LTD. Toshihide Kurihara: Ministry of Education, Culture, Sports, Science, and Technology in Japan (MEXT) KAKENHI, Charitable
Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical’s Founder, Uehara Memorial Foundation, Takeda Science Founda-
tion, Tsubota Laboratory, Inc, Fuji Xerox Co, Ltd, Kirin Company, Ltd, Novartis Pharmaceuticals Japan, Santen Pharmaceutical Co Ltd, andOtsuka Phar-
maceutical Co, Ltd; awards from the Japanese Retina and Vitreous Society, International Myopia Conference (IMC), Keio University School of Medicine
Alumni Association (Sanshikai), ARVO/Alcon Foundation, and Keystone Symposia. Kazuo Tsubota: grant-in-aid ‘‘A Scheme to Revitalize Agriculture
and Fisheries in Disaster Area through Deploying Highly Advanced Technology’’ from the Ministry of Agriculture, Forestry, and Fisheries of Japan; Alcon
Research LTD, OPHTECS Co, Ltd, ROHTO Pharmaceutical Co, Ltd, Dai Nippon Printing Co, Ltd, Santen Pharmaceutical Co Ltd, QD Laser, Inc,
R-Tech Ueno, Ltd, Tsubota Laboratory, Inc, Plaza Eye Co, Ltd, Ogura Co, Ltd, TAKATAOPTICAL CO, LTD, Otsuka Pharmaceutical Co, Ltd,
Kowa Company, Ltd, JIN CO, LTD,Wakamoto Pharmaceutical Co, Ltd, Toray Industries, Inc, Meiji Co, Ltd, Yamada Bee Farm Co, Ltd, Pfizer Inc, Kissei
Pharmaceutical Co, Ltd, White Medical Co Ltd, Wakasa Seikatsu Co, Ltd, Senju Pharmaceuticals Co, Ltd. Yoko Ozawa: Grant-in-Aid for Scientific
Research, JSPS KAKENHI (24592647), Grant-in-Aid, ‘‘A Scheme to Revitalize Agriculture and Fisheries in Disaster Area through Deploying Highly
Advanced Technology,’’ from theMinistry of Agriculture, Forestry, and Fisheries of Japan,Wakasa Seikatsu Co, Ltd, JINS Co, Ltd, Santen Pharmaceutical
Co Ltd, Novartis Pharmaceuticals Japan, Alcon Research LTD, Bayer AG, Senju Pharmaceuticals Co, Ltd. The following authors have no disclosures:
Yohei Tomita, Mamoru Kamoshita, and Chigusa Iyama. All authors attest that they meet the current ICMJE criteria for authorship.JUNE 2016OPHTHALMOLOGY
REFERENCES
1. Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III
clinical trial results. Ophthalmol Clin North Am 2006;19(3):
361–372.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for
neovascular age-related macular degeneration. N Engl J Med
2006;355(14):1419–1431.
3. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept
(VEGF trap-eye) in wet age-related macular degeneration.
Ophthalmology 2013;119(12):2537–2548.
4. SuzukiM,Nagai N, Izumi-Nagai K, et al. Predictive factors for
non-response to intravitreal ranibizumab treatment in age-
related macular degeneration. Br J Ophthalmol 2014;98(9):
1186–1191.
5. Tsujikawa A, Ojima Y, Yamashiro K, et al. Association of
lesion size and visual prognosis to polypoidal choroidal
vasculopathy. Am J Ophthalmol 2011;151(6):961–972.
6. Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders
to bevacizumab (Avastin) therapy of choroidal neovascular
lesions. Br J Ophthalmol 2007;91(10):1318–1322.
7. Hoerster R, Muether PS, Sitnilska V, Kirchhof B, Fauser S.
Fibrovascular pigment epithelial detachment is a risk factor
for long-term visual decay in neovascular age-related macular
degeneretion. Retina 2014;34(9):1767–1773.
8. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M,
Simader C. Pigment epithelial detachment followed by
retinal cystoid degeneration leads to vision loss in treatment
of neovascular age-related macular degeneration. Ophthal-
mology 2015;122(4):822–832.
9. Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical
characteristics of exudative age-related macular degeneration
in Japanese patients. Am J Ophthalmol 2007;144(1):15–22.
10. Liu Y, Wen F, Huang S, et al. Subtype lesions of neovascular
age-related macular degeneration in Chinese patients.
Graefes Arch Clin Exp Ophthalmol 2007;245(10):1441–1445.
11. Sasaki M, Kawasaki R, Uchida A, et al. Early signs of exuda-
tive age-related macular degeneration in Asians. Optom Vis
Sci 2014;91(8):849–853.
12. Spaide RF, Yannuzzi LA, Slakter JS, Sorenson J, Orlach DA.
Indocyanine green videoangiography of idiopathic polypoidal
choroidal vasculopathy. Retina 1995;15(2):100–110.
13. Yannuzzi LA, Negrao S, Iida T, et al. Retinal angiomatous
proliferation in age-related macular degeneration. Retina
2001;21(5):416–434.
14. Yannuzzi LA, Ciardella A, Spaide RF, Rabb M, Freund KB,
Orlock DA. The expanding clinical spectrum of idiopathic
polypoidal choroidal vasculopathy. Arch Ophthalmol 1997;
115(4):478–485.
15. Maruko I, Iida T, Saito M, Nagayama D. Combined cases of
polypoidal choroidal vasculopathy and typical age-related
macular degeneration. Graefes Arch Clin Exp Ophthalmol
2010;248(3):361–368.
16. Koh A, Lee WK, Chen LJ, et al. EVEREST study: efficacy
and safety of verteporfin photodynamic therapy in combi-VOL. 166 POLYPOIDAL CHOROIDAL VASCULOnation with ranibizumab or alone versus ranibizumab
monotherapy in patients with symptomatic macular poly-
poidal choroidal vasculopathy. Retina 2012;32(8):
1453–1464.
17. Oishi A,Miyamoto N,MandaiM, et al. LAPTOP study: a 24-
month trial of verteporfin versus ranibizumab for polypoidal
choroidal vasculopathy. Ophthalmology 2014;121(5):
1151–1152.
18. Gomi F, Sawa M, Sakaguchi H, et al. Efficacy of intravitreal
bevacizumab for polypoidal choroidal vasculopathy. Br
J Ophthalmol 2008;92(1):70–73.
19. Gomi F, Sawa M, Wakabayashi T, Sasamoto Y, Suzuki M,
Tsujikawa M. Efficacy of intravitreal bevacizumab
combined with photodynamic therapy for polypoidal
choroidal vasculopathy. Am J Ophthalmol 2010;150(1):
48–54.e1.
20. Gomi F, Oshima Y,Mori R, et al. Initial versus delayed photo-
dynamic therapy in combination with ranibizumab for treat-
ment of polypoidal choroidal vasculopathy: The Fujisan
Study. Retina 2015;35(8):1569–1576.
21. Tsujikawa A, Ooto S, Yamashiro K, Tamura H, Otani A,
Yoshimura N. Treatment of polypoidal choroidal vasculop-
athy by intravitreal injection of bevacizumab. Jpn J Ophthal-
mol 2010;54(4):310–319.
22. Kulkarni AD, Kuppermann BD. Wet age-related macular
degeneration. Adv Drug Deliv Rev 2005;57(14):1994–2009.
23. Kawamura A, Yuzawa M, Mori R, Haruyama M, Tanaka K.
Indocyanine green angiographic and optical coherence tomo-
graphic findings support classification of polypoidal choroidal
vasculopathy into two types. Acta Ophthalmol 2013;91(6):
e474–481.
24. Yanagisawa S, Sakurada Y, Miki A, Matsumiya W, Imoto I,
Honda S. The association of elastin gene variants with two
angiographic subtypes of polypoidal choroidal vasculopathy.
PLoS One 2015;10(3):e0120643.
25. Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal
choroidal vasculopathy and neovascularized age-related mac-
ular degeneration. Arch Ophthalmol 1999;117(11):
1503–1510.
26. Tanaka K, Nakayama T, Mori R, et al. Associations of com-
plement factor H (CFH) and age-related maculopathy sus-
ceptibility 2 (ARMS2) genotypes with subtypes of
polypoidal choroidal vasculopathy. Invest Ophthalmol Vis Sci
2011;52(10):7441–7444.
27. Coscas G, Lupidi M, Coscas F, et al. Toward a specific classi-
fication of polypoidal choroidal vasculopathy: idiopathic dis-
ease or subtype of age-related macular degeneration. Invest
Ophthalmol Vis Sci 2015;56(5):3187–3195.
28. Yuzawa M. Two subtypes of polypoidal choroidal vasculop-
athy: idiopathic disease or age-related macular degeneration.
Invest Ophthalmol Vis Sci 2015;56(6):3998.
29. Mori R, Yuzawa M, Akaza E, Haruyama M. Treatment results
at 1 year of ranibizumab therapy for polypoidal choroidal
vasculopathy in eyes with good visual acuity. Jpn J Ophthalmol
2013;57(4):365–371.59PATHY WITH MULTIPLE POLYPS
